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MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR-γ agonist that lowers glucose in the absence of some of the
side eﬀects, such as weight gain and edema, that are observed with the TZDs. Interestingly MBX-102 also displays pronounced
triglyceride lowering in preclinical rodent models and in humans. Although in vitro reporter gene studies indicated that MBX-102
acid is a highly selective PPAR-γ agonist that lacks PPAR-α activity, we sought to determine if PPAR-α activation in vivo could
possibly contribute to the triglyceride lowering abilities of MBX-102. In vivo studies using ZDF and ZF rats demonstrated that
MBX-102 lowered plasma triglycerides. However in ZF rats, MBX-102 had no eﬀect on liver weight or on hepatic expression
levels of PPAR-α target genes. Further in vitro studies in primary human hepatocytes supported these ﬁndings. Finally, the ability
of MBX-102 to lower triglycerides was maintained in PPAR-α knockout mice, unambiguously establishing that the triglyceride
lowering eﬀe c to fM B X - 1 0 2i sP P A R - α independent. The in vivo lipid lowering abilities of MBX-102 are therefore mediated by an
alternate mechanism which is yet to be determined.
Copyright © 2009 Apurva Chandalia et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
T h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r s( P P A R s )
belong to the nuclear hormone receptor superfamily of
transcription factors. They are lipid sensors known to govern
numerous biological processes. The three PPAR subtypes (α,
δ (β), and γ) regulate the expression of numerous genes
involved in a variety of metabolic pathways [1, 2]. PPAR-
γ is expressed most abundantly in adipose tissue and is
a master regulator of adipogenesis and mediates the anti-
diabetic activity of the marketed insulin-sensitizing drugs
that belong to the thiazolidinedione (TZD) class-such as
rosiglitazone (Avandia) and pioglitazone (Actos). PPAR-α
is highly expressed in the liver and is the molecular target
for the ﬁbrates (e.g., fenoﬁbrate and gemﬁbrozil), a class
of drugs that lower plasma triglycerides and increase HDL
levels in humans [3, 4]. The function of PPAR δ(β)i s
still not fully understood but recent evidence suggests that
this ubiquitously expressed PPAR isoform has pleiotropic
actions that may govern diverse physiological processes,
including the regulation of lipid and lipoprotein metabolism
[5, 6], insulin sensitivity [7], cardiac function [8], epidermal
biology [9], neuroprotection [10], and gastrointestinal tract
function and disease [11].
As indicated above, the clinical relevance of PPAR-γ
agonistsishighlightedbythecurrentlymarketedantidiabetic
blockbuster drugs, Avandia, and Actos. These drugs behave
as selective PPAR-γ full agonists as they are potent and
selective activators of PPAR-γ [12]. In humans, they enhance
insulin action, improve glycemic control with a signiﬁcant
reduction in the level of glycohaemoglobin (HbA1C), and
have variable eﬀects on serum triglyceride levels in patients
with type 2 diabetes [13]. Despite their proven eﬃcacy,
they possess a number of deleterious side eﬀects, including
signiﬁcant weight gain and peripheral edema [14–16],
increased risks of congestive heart failure, and increased rate
of bone fracture [15, 17, 18].2 PPAR Research
The weight gain associated with the use of TZDs is
observed in preclinical species and in humans [15, 19]
and is likely due to multiple interacting factors, including
increased adiposity and ﬂuid retention [17, 20]. Fluid
retention and subsequent edema are the most signiﬁcant
undesired eﬀects of TZD treatment. Edema is a prominent
problem in patients taking TZDs particularly those who are
also taking insulin or sulfonylureas. In susceptible patients
with pre-existing conditions, ﬂuid retention and edema can
lead to an increased incidence of congestive heart failure
[21]. Moreover the inference that TZD treatment cause a
signiﬁcant increase in the risk of myocardial infarction and
an increase in the risk of death from cardiovascular in type 2
diabetic patients wasrecentlymade[22,23],leadingtheFDA
to request the addition of a black box warning to the label of
both Actos and Avandia.
Another major side eﬀect of glitazone use is related
to their detrimental skeletal actions as they are known to
c a u s eb o n el o s si nr o d e n t s[ 24–26]. More importantly, TZDs
treatment was recently shown to decrease bone formation
and accelerated bone loss in healthy and insulin resistant
individuals and/or to increase the fracture rate in diabetic
women treated with TZDs [27, 28]. Such major safety
concerns have not only restrained the clinical use of these
drugs but have also led to development failure of a large
number of PPAR agonists [15, 17].
During the last decade, a major investment was made by
the pharmaceutical industry to develop safer PPAR agonists
(reviewed in [20, 29]). This eﬀort led to the description of
several unique TZD-like and non-TZD-like partial PPAR-
γ agonists that display insulin-sensitizing activity associated
with lower stimulation of adipogenesis and therefore with a
potential for reduced side eﬀects [15, 17, 20, 30–33].
MBX-102/JNJ39659100 (MBX-102) is a compound in
development for the treatment of type 2 diabetes. It is
a single enantiomer of halofenate, a drug developed for
lipid lowering that was tested clinically in the 1970s as a
hypolipidemic and hypouricemic agents [34, 35]. Studies
with halofenate in diabetic patients also demonstrated
signiﬁcant eﬀects on plasma glucose and insulin [36, 37],
suggesting insulin sensitizing properties. It was recently
discovered that both halofenate and MBX-102 are selective
partial PPAR-γ modulators thereby oﬀering an explanation
for their anti-diabetic properties and lack of weight gain and
edema [20, 38].
The results presented here show, in agreement with
the published halofenate data, that MBX-102 also displays
signiﬁcanttriglycerideloweringinpreclinicalrodentmodels.
Astriglyceridesloweringinpreclinicalspeciesandinhumans
is often considered a hallmark of PPAR-α activation and
because the mechanism of action by which halofenate lowers
triglycerides has not been elucidated, we performed a series
of studies to assess if PPAR-α activation could possibly play a
role in the hypolipidemic eﬃcacy of MBX-102.
2.MaterialandMethods
2.1. Chemicals. MBX-102, pioglitazone, and rosiglitazone
maleate were synthesized at Metabolex (Metabolex Inc,
Hayward,CA).FenoﬁbrateandGW7647wereobtainedfrom
Sigma-Aldrich (Saint-Louis, MO). WY-14643 was obtained
from Eagle Picher Pharmaceutical Services (Lenexa, KS).
2.2. Cell-Based Reporter Assays. The determination of mouse
PPAR-α, δ,a n dγ activation was performed as previously
described[38].Brieﬂy,HEK-293Tcellsweretransfectedwith
Gal4 chimeras and reporter gene plasmids using Lipofec-
tamine 2000 (InVitrogen, Carlsbad, CA) and incubated for
4 hours before treatment with compound for 20–24 hours.
Expression was assayed using the Steady-Glo assay system
(Promega, Madison, WI).
2.3. Human Primary Hepatocytes. Cryo-preserved primary
human hepatocytes were obtained from Celsis (Baltimore,
M D ) .C e l l sw e r eq u i c k l yt h a w e di na3 7 ◦Cw a t e rb a t h
and placed into 5mL of warm InvitroGRO CP medium
(Celsis Baltimore, MD) with 2.2% Torpedo antibiotic (Celsis
Baltimore, MD). A total of 350000cells/well were plated
in 24-well collagen-coated plates (Becton Dickinson, San
Jose, CA) and incubated overnight. The following day the
media was replaced with fresh InvitroGRO HI medium
(Celsis Baltimore, MD) containing either DMSO (0.5%) or
the test compounds, and the cells were incubated for 24
hours. Cells were then harvested and processed for gene
expression analysis. Total RNA was isolated using Trizol
(Invitrogen, Carlsbad, CA), and cDNA was prepared by
reverse transcription using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA). RT-
PCR (Taqman) was performed in 96-well plates containing
Taqman fast universal PCR master mix (Applied Biosystems,
Foster City, CA) and the appropriate gene expression assay
mixes for human HADHB, HMGCS2, CYP4a11, and RPLP0
(Applied Biosystems, Foster City, CA). The “fold change
versus vehicle” in gene expression was calculated using
the comparative Ct method for relative quantiﬁcation. For
each compound, two to ﬁve independent experiments were
performed, and in each experiment the compounds were
tested in at least 2 replicate wells. The “fold change versus
vehicle” data for replicate experiments were pooled prior to
statistical analysis.
2.4. In Vivo Studies. The Metabolex Institutional Animal
Care and Use Committee approved all animal care and
experimental procedures described below. All animals were
housed in temperature (22 ± 3◦C) and humidity (55 ± 4%)
controlled rooms, with 12 hour light (6AM-6PM)/dark
cycle. Unless speciﬁed otherwise, mice were housed 4 to 5
mice/cage,andratswerehoused2rats/cageandwereallowed
adlibitum access to tap water and Purina Rodent Chow
(Laboratory Rodent Diet 5001, St. Louis, Mo., USA).
2.4.1. Reagents and Assays. Plasma glucose levels were mea-
sured using the method of Trinder [39] (Glucose Oxidase
G7016, Peroxidase P8125, Sigma Chemical Co., St. Louis,
MO).Plasmatriglyceridesweremeasuredusingatriglyceride
Diagnostic Kit (Sigma Chemical Co., MO). Plasma-free fatty
acid (FFA) levels were measured using the HR Series NEFA-
HR [2] (Wako, Richmond, VA). Plasma insulin levels werePPAR Research 3
determined using either a rat or a mouse insulin EIA kit
(ALPCO Chem. Windham, NH).
2.4.2. Zucker Diabetic Fatty Rat Study. 9w e e k - o l dZ u c k e r
diabetic fatty (ZDF) rats were obtained from Charles River
(Boston, MA). Vehicle and drug suspensions were adminis-
tered to the rats daily by oral gavage for 11 days. Six rats were
assigned to each of the following groups: Vehicle (10mL/kg),
rosiglitazone maleate (4mg/kg), and MBX-102 (100mg/kg).
Body weight and food intake were recorded weekly. On day
11, rats were fasted for 6 hours and blood samples (∼500μL)
were collected via cardiac puncture at the time of necropsy.
2.4.3. Zucker Fatty Rat Study. 10 week-old male Zucker
Fatty (ZF) rats were obtained from Harlan (Indianapolis,
IN). Vehicle and drug suspensions were administered to
the rats daily by oral gavage for 32 days. Eight rats
were assigned to each of the following groups: ZF Vehicle
(5mL/kg), ZF + fenoﬁbrate (450mg/kg), and ZF + MBX-
102(100mg/kg).Bodyweightandfoodintakewererecorded
every 2 or 3 days in the fed state until day 28 of the
study. At day 33 (24 to 28 hours post-last dose), blood
samples were collected following a 6 hour fast from each
rat via cardiac puncture for total triglyceride and insulin
determinations. Liver weights were also recorded. Follow-
ing necropsy, a small (∼100–200mg) section of liver was
excised, placed into a cryovial and immediately frozen in
liquid nitrogen. Tissue homogenates for gene expression
analysis were prepared as follows: frozen liver samples were
placed into a 2mL homogenization vial containing HTG
tissue lysis buﬀer (1mL/100mg of tissue, High Throughput
Genomics, Tucson, AZ) and a 5mm steel bead. Tissues were
homogenized for 5 minutes (25pulses/second) in a Qiagen
Tissue Lyser. Homogenates were heated at 95◦Cf o r1 0
minutes, frozen at −80◦C, and shipped to high throughput
genomics(HTG,Inc.,Tuscson,AZ)formRNAmeasurement
using a custom qNPA multiplex array. The HTG quantitative
nuclease protection (qNPA) technology was used to analyze
changes in mRNA expression levels. All raw values were
obtained by imaging with a high-resolution imager and were
normalized against two endogenous house keeping genes,
RPL10a (rat ribosomal protein L10A) and Arbp (rat acidic
ribosomal phosphoprotein P0). For the treatment groups,
the fold changes (FC) were calculated using the Vehicle-
treated values as 100% (FC = 1).
2.4.4. PPAR-α KO Study. Male wild-type (C57BL/6N)
and PPAR-α knockout mice (B6.129S4-Pparatm1Gonz,o n
C57BL/6N background, N12) were received from Taconic
(Germantown, New-York) at 4–6 weeks of age. Animals were
allowed access adlibitum to tap water and Rodent Chow
(RD D12450B, New Brunswick, NJ). Ten wild-type (WT)
and 10 knockout (KO) mice were assigned to each of the
followinggroups:vehicle(5mL/kg),WY-14643(130mg/kg),
and MBX-102 (200mg/kg). Compounds or vehicle were
delivered by oral gavage once daily for 7 days. At the end
of the drug treatment, blood samples from each mouse were
collected, following a 6 hour fast, via cardiac puncture for
total triglyceride and free fatty acid determinations. Three
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Figure 1: Chemical structures of the prodrug ester (a) and active-
free acid form (b).
independent studies were performed to evaluate the ability
of MBX-102 to lower triglycerides in WT and KO mice.
Datasets obtained from the 3 studies were pooled prior to
statistical analysis.
2.5. Statistical Analysis. Data are expressed as mean ± SEM.
Prism software (GraphPad v 5.01, San Diego, CA) was used
for all statistical analyses. Unless speciﬁed otherwise in the
ﬁgure legends, 1-way ANOVA followed by either Tukey’s
multiple comparison test or Newman-Keul multiple com-
parison test or 2-way ANOVA followed by Bonferroni post
test was used to assess statistical diﬀerences between groups.
All P-values of less than .05 were considered statistically
signiﬁcant.
3. Result
MBX-102/JNJ-39659100 (Figure 1(a)) is the (–) enantiomer
of halofenate, a drug previously described as a partial PPAR-
γ agonist [38]. MBX-102 is a prodrug ester (Figure 1(a)),
that is rapidly and completely modiﬁed in vivo by non-
speciﬁc serum esterases to the mature free acid form MBX-
102 acid (Figure 1(b)), which is the circulating form of the
drug. For these reasons MBX-102 was utilized for in vivo
studies, whereas the acid form was utilized for all in vitro
studies.
Aspreviouslydescribedforhalofenate,cell-basedinvitro
studies revealed that MBX-102 acid also behaves as a selec-
tive, weak partial PPAR-γ agonist. As shown in Figure 2(a),
a dose-dependent activation of mouse GAL4-PPAR-γ was
observed in response to MBX-102 acid and rosiglitazone,
with EC50so f∼12μM for MBX-102 acid and ∼1.5μMf o r
rosiglitazone. Compared to the full agonist rosiglitazone,
MBX-102 acid was a much weaker transactivator of PPAR-
γ, as indicated by its lower transactivation activity (∼10% of
that observed with rosiglitazone). MBX-102 acid selectivity
toward PPAR-γ was conﬁrmed by the lack of transactivation
of mouse GAL4-PPAR-α or δ (Figures 2(b) and 2(c)). A
similar PPAR activation proﬁle of MBX-102 acid was also
observed for human and rat PPARs, including selectivity
for PPAR-γ, partial agonism, and similar EC50s for PPAR-γ
activation (data not shown).
Halofenate was initially developed as a hypolipidemic
agent, and MBX-102 is reported to share this ability. In order
to assess MBX-102 eﬃcacy we evaluated the lipid lowering4 PPAR Research
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Figure 2: Gal4 Reporter assay data for mouse PPAR-γ (a), mouse PPAR-α (b), and mouse PPAR-δ (c). Values are plotted as mean ± SEM
and are representative of at least 2 independent experiments.
properties of MBX-102 as well as its antidiabetic eﬀects,
using the male Zucker Diabetic Fatty (ZDF) rat model. ZDF
ratsweretreatedwithMBX-102(100mg/kg)orrosiglitazone
(4mg/kg) for 11 days. As shown in Figure 3,a f t e ra6
hours fast, MBX-102 signiﬁcantly decreased triglyceride
(Figure 3(b)), free fatty acid (Figure 3(c)), and cholesterol
(Figure 3(d)) levels. The magnitude of reduction in these
lipid parameters was signiﬁcantly higher than what was
observed for rosiglitazone (TG 89% versus 57%; FFA 86%
versus 49% and Cholesterol 57% versus 10%, for MBX-102
and rosiglitazone, resp.), suggesting superior hypolipidemic
activity of MBX-102 compared to rosiglitazone. Moreover,
both MBX-102 and rosiglitazone signiﬁcantly reduced fast-
ing blood glucose (Figures 3(a) and 3(e)), conﬁrming that
MBX-102 is an eﬃcacious antidiabetic agent. This eﬀect
was anticipated as antidiabetic properties including glucose
lowering, and insulin sensitization in preclinical models is a
hallmark of full PPAR-γ agonists and has also been reported
for partial agonists [20]. In addition, signiﬁcant increases
in body weight (Figure 4(a)) and adipose tissue weight
(Figure 4(b)) were observed with rosiglitazone treatment
only, indicating that MBX-102 does not display the classical
weight gain eﬀects of the full PPAR-γ agonists.
In order to evaluate further the lipid lowering ability of
MBX-102, male Zucker Fatty (ZF) rats, a well-established
model for hypertriglyceridemia and obesity, were used. The
PPAR-α agonist fenoﬁbrate, a known triglyceride lowering
agent, was included in the study as a comparator. As ZFPPAR Research 5
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Figure 3: Eﬀect of MBX-102 (100mg/kg) and rosiglitazone (4mg/kg) on fasting plasma glucose (a), triglycerides (b), FFA (c), and
cholesterol (d) levels during the course of treatment of male ZDF rats. Values are plotted as mean ± SEM (∗: P<. 05, ∗∗: P<. 01,
∗∗∗: P<. 001 versus ZDF vehicle; #: P<. 05, ##: P<. 01, ###: P<. 001 versus MBX-102-treated group, 2-way ANOVA followed by
Bonferroni post tests). (e) Fasting plasma glucose, insulin, triglycerides, and FFA levels on day 11. Values are plotted as mean percentage of
vehicle ± SEM (NS: P>. 05, ∗: P<. 05, ∗∗: P<. 01, ∗∗∗: P<. 001 versus ZDF vehicle, ##: P<. 01 versus MBX-102-treated group, 1-way
ANOVA and Tukey’s multiple comparison test).6 PPAR Research
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Figure 4: Eﬀect of MBX-102 (100mg/kg) and rosiglitazone
(4mg/kg) on body weight (BW) (a) and white adipose tissue
weights (b) after 11 days of treatment of male ZDF rats. For the
adipose tissue weight, the values are plotted as mean percentage of
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multiple comparison test).
rats are hyperinsulinemic and insulin resistant, the insulin
sensitizing eﬀect of MBX-102 was also assessed. ZF male
rats were treated with either vehicle, fenoﬁbrate (450mg/kg)
or MBX-102 (100mg/kg) for 32 days. In this study, no
signiﬁcant diﬀerences in body weight or food intake were
observed upon drug treatment (data not shown). As shown
in Figure 5(a), both MBX-102 and fenoﬁbrate treatment
signiﬁcantly lowered fasting plasma insulin after 32 days of
treatment. However, the reduction observed for MBX-102-
treated ZF rats was signiﬁcantly greater when compared to
the reduction observed for the fenoﬁbrate-treated animals.
In this rat model, MBX-102 robustly decreased fasting
plasma triglycerides after 32 days of treatment (Figure 5(b)).
Although fenoﬁbrate also led to a reduction in plasma
triglyceride levels, the reduction was less pronounced when
compared to MBX-102 (31% versus 60%, Figure 5(b)).
To determine if PPAR-α activation might be responsible
for the triglyceride lowering ability of MBX-102, liver weight
and liver gene expression levels of several PPAR-α responsive
genes were assessed in this study. As shown in Figure 5(c),
fenoﬁbrate treatment markedly increased liver weight while
MBX-102 treatment caused minimal change in this param-
eter. In addition, a slight but not statistically signiﬁcant
upregulation of ACO (Figure 6(a)), signiﬁcant upregulation
of HADHB (Figure 6(b)), and signiﬁcant downregulation of
apoC-III (Figure 6(c))m R N Al e v e l sw e r ea l s od e t e c t e du p o n
treatment with fenoﬁbrate. In contrast, MBX-102 treatment
had no eﬀect on the mRNA expression levels of these three
PPAR-α responsive genes, suggesting that MBX-102 lowered
triglycerides independently of PPAR-α activation.
In order to further explore the PPAR selectivity of MBX-
102 in a physiologically relevant cell-based system, primary
human hepatocytes were used to evaluate the expression
levels of several PPAR-α responsive genes. Primary human
hepatocytes were treated with known PPAR-α agonists
including GW7647, WY-14643, and fenoﬁbric acid as well
as with the PPAR-γ agonists rosiglitazone, pioglitazone, and
MBX-102acid.AsshowninFigure 7,HADHB(a),HMGCS2
(b), and CYP4a11 (c) mRNA levels were signiﬁcantly upreg-
ulated by treatment with all PPAR-α agonists. The extent
of upregulation was similar for all three PPAR-α agonists.
Interestingly, these three genes were also signiﬁcantly up-
regulated by pioglitazone although the magnitude of this
eﬀectwaslessthanforthethreePPAR-αagonists.Incontrast,
althoughMBX-102acidtreatmentwasabletoinducemRNA
levels of the PPAR-γ responsive genes CD36 and FABP4 in
these cells (data not shown), it had no eﬀect on any of the
PPAR-α responsive gene tested supporting the in vivo results
observed in the ZF rats.
Based on these results, we speculated that MBX-102
would be able to lower triglycerides in mice lacking PPAR-α.
Therefore, the eﬀect of MBX-102 on triglyceride levels was
evaluated in wild-type (WT) and PPAR-α knockout (KO)
mice. WT and KO mice were treated with either vehicle, the
PPAR-α selective agonist WY-14643 (130mg/kg), or MBX-
102 (200mg/kg) for 7 days. Prior to evaluating triglyceride
lowering, single, and repeated doses, pharmacokinetic anal-
yses were performed with both compounds in both WT
and KO mice, and no diﬀerence in plasma drug exposure
was observed (data not shown). As shown in Figure 8(a),
treatment with WY-14643 signiﬁcantly reduced plasma
triglycerides in WT mice. This eﬀect was totally abolished in
the PPAR-α KO mice, conﬁrming that PPAR-α was required
for this eﬀect. In contrast, a signiﬁcant reduction in plasma
triglycerides was observed upon treatment with MBX-102
both in WT and PPAR-α KO mice, demonstrating this eﬀect
was independent of PPAR-α activation. Plasma FFA levels in
WT and KO mice are depicted in Figure 8(b).C o m p a r e dt o
vehicle-treated WT mice, plasma FFA levels were markedly
elevated in vehicle-treated KO mice. Treatment with WY-
14643hadlittle(WT)tonoeﬀect(KO)onplasmaFFAlevels.PPAR Research 7
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Figure 5: Eﬀect of MBX-102 (100mg/kg) and fenoﬁbrate
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MBX-102(100mg/kg)orfenoﬁbrate(450mg/kg).Expressionlevels
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mean ± SEM (NS: P>. 05, ∗∗∗: P<. 001 versus Vehicle-treated,
1-way ANOVA, and Newman-Keuls multiple comparison test).8 PPAR Research
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Figure 7: Eﬀect of PPAR-α agonists, rosiglitazone, pioglitazone, and MBX-102 acid on HADHB (a), HMGCS2 (b), and CYP4a11 (c) mRNA
levels in primary human hepatocytes. Values represent mean ± SEM (∗: P<. 05, ∗∗∗: P<. 001 versus Vehicle-treated, 1-way ANOVA and
Tukey’s multiple comparison test).
In contrast, although MBX-102 had no impact on FFA levels
in WT mice, it led to signiﬁcant FFA lowering in the KO
animals (Figure 8(b)). At the end of the study changes in
liver weight upon compound treatment were evaluated. As
expected,treatmentwithWY-14643increasedliverweightby
52% in WT mice, and the eﬀect was totally abolished in the
PPAR-α KO mice (Figure 8(c)). MBX-102 treatment mildly
increased liver weight to a similar extent in both WT and KO
mice, indicating this eﬀect occurred independently of PPAR-
α activation.
4. Discussion
Type 2 diabetes mellitus is a chronic disease characterized
by glucose intolerance, hyperinsulinemia, and dyslipidemia,
[40]. PPAR-γ agonists such as rosiglitazone and pioglitazone
belongtothethiazolidinedione(TZD)classandarecurrently
in clinical use for lowering glucose levels in diabetes [41, 42].
Our results show that MBX-102 acid, a non-TZD PPAR
agonist, is a partial, selective PPAR-γ agonist which has
the potential to oﬀer antidiabetic eﬃcacy comparable toPPAR Research 9
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Figure 8: Eﬀect of MBX-102 (200mg/kg) and WY-14643
(130mg/kg) on plasma triglyceride levels (a), FFA levels (b), and
liver weights (c) in WT and KO mice after 7 days treatment of
PPAR-α KO mice. Values represent mean ± SEM (∗: P<. 05, ∗∗∗:
P<. 001 versus Vehicle, 2-way ANOVA, and Bonferroni post-tests).
rosiglitazone. More importantly, compared to rosiglitazone,
treatment of ZDF rats with MBX-102 did not signiﬁcantly
aﬀect body weight and white adipose tissue mass, suggesting
that in humans, MBX-102 will not display the classical
adverse eﬀects of the full PPAR-γ agonists [15, 20]. These
dataareinagreementwithapreviouslypublishedreportthat
established that halofenate, the racemic mixture from which
MBX-102 is derived, had comparable insulin sensitization to
rosiglitazone in the absence of body weight gain [38].
Among the eﬃcacy parameters measured in our stud-
ies, the most diﬀerentiating feature of MBX-102 was its
impressive lipid lowering abilities. MBX-102 was much more
eﬃcacious than rosiglitazone and fenoﬁbrate at lowering
plasma triglycerides in the diabetic, insulin-resistant rat
models tested. In rodents, diﬀerences in feeding behavior
caninduce signiﬁcant ﬂuctuationin plasma triglyceridesand
free fatty acid levels. Such an artifact can be excluded in the
p r e s e n ts t u d i e sa sa l lm e a s u r e m e n t sw e r ep e r f o r m e do n6
hour post-fasting plasma samples.
In the clinical setting, ﬁbrate therapy is known to achieve
signiﬁcant triglyceride lowering, an expected feature of
PPAR-α agonists [43, 44]. In contrast, the lipid eﬀects of the
marketed PPAR-γ agonists are not as clear, as pioglitazone
displays beneﬁcial eﬀects on lipid proﬁle in diabetic patients
while rosiglitazone does not [13, 45]. Our data suggest that
MBX-102 will display beneﬁcial eﬀects on lipid proﬁle in
humans, and this was recently conﬁrmed in a phase 2a
clinical trial [46]. Overall, these results are not unexpected
based on the history of halofenate, the parent molecule from
whichMBX-102wasderived.Halofenatewastestedclinically
in the 1970s as a hypolipidemicand hypouricemic agent and
was shown to lower serum triglycerides and uric acid in
patients with a variety of hyperlipidemias [36, 37, 47–49].
Although the mechanism by which halofenate and MBX-
102 reduce triglycerides in preclinical rodent models and in
humans remains unclear, a major concern was that MBX-
102 may exert its hypolipidemic action through PPAR-
α activation. As mentioned above, triglyceride lowering is
a well-known feature of PPAR-α agonists. Although the
classical in vitro reporter gene assays we used to assess MBX-
102 selectivity toward PPAR-γ clearly show their inability to
transactivate human, mouse, or rat PPAR-α, the biological
relevance of these assays remains unclear as they do not truly
represent the interaction between the ligand and its receptor
in a physiologically relevant setting [17]. The discontinua-
tion of several dual α/γ PPAR agonists at mid to late stage of
development due to major safety concerns including dose-
limiting toxicities and carcinogenicity-related issues clearly
highlights the potential for increased risk of safety liabilities
for dual agonists compared to selective agonists [15, 17]. The
carcinogenic risk is of particular interest as duals agonists
appear to have enhanced rodent carcinogenicity poten-
tial compared to selective gamma agonists (http://www.
fda.gov/cder/present/DIA2004/Elhage.ppt), increasing the
burden of developing such agents for use in humans.
Therefore in order to demonstrate that MBX-102 can lower
triglycerides independently of PPAR-α activation, we under-
took a series of studies in which we used physiologically
relevant readouts of PPAR-α activation.10 PPAR Research
Although both fenoﬁbrate and MBX-102 had the ability
to modulate triglyceride levels in ZF rats, MBX-102 only
had a small eﬀect on rat liver, which is unlikely mediated
by PPAR-α activation as MBX-102 treatment led to a similar
liver weight increase in PPAR-α KO mice. Moreover, MBX-
102 was unable to regulate the hepatic expression levels
of the 3 known PPAR-α target genes tested, suggesting its
inability to transactivate rat PPAR-α in vivo. In contrast,
the anticipated regulation of these genes (i.e., upregula-
tion of 2 key genes involved in fatty acid oxidation and
downregulation of apoC-III) was observed with fenoﬁbrate
[50, 51].
Primary human hepatocytes representa biologicallyrele-
vantcelllinetomodelclinicaleﬀectsofPPAR-αagonismand
therefore were used to further explore the PPAR selectivity
of MBX-102 acid. In this cell-based system, we were unable
to detect any induction of PPAR-α responsive genes upon
MBX-102 acid treatment, further conﬁrming its lack of
PPAR-α activity. Moreover, the ﬁnding that MBX-102 still
lowerstriglyceridesinPPAR-αdeﬁcientmiceunambiguously
demonstrates that MBX-102 can lower triglycerides eﬀec-
tively in the absence of PPAR-α.
Although these results corroborate that MBX-102 is
a selective PPAR-γ agonist, the mechanism by which it
lowers triglycerides in preclinical species and in the clinic
still needs to be addressed. Pioglitazone also possesses
triglycerideloweringeﬀectsinhumansbutinthiscasepartial
contribution of PPAR-α activation cannot be ruled out. Our
hepatocyte data indeed show that pioglitazone upregulates
PPAR-α responsive genes, in agreement with published
reports showing that pioglitazone binds to and activates
the human PPAR-α receptor [52]. Moreover, pioglitazone
has recently been shown to raise hepatic apoA-I and HDL
through a PPAR-α-dependent pathway [53].
Studies performed in the 1970s with halofenate may pro-
vide a potential clue as to how MBX-102 lowers triglycerides.
In normal rats, sustained reduction of serum triglyceride
levels upon treatment with halofenate was suggested to
be mediated through the inhibition of hepatic triglyceride
formation.Althoughthemechanismofactionmediatingthis
eﬀect is not yet elucidated, it was also suggested that the
inhibition of hepatic triglyceride formation might be related
to drug-induced decreases in the availability of fatty acids
for triglyceride synthesis [54]. Our results in ZDF rats are
in agreement with this hypothesis as a marked lowering of
circulating free fatty acids was indeed observed upon MBX-
102 treatment.
Taken as a whole, the data from these studies provide
deﬁnitive evidence that MBX-102 acid does not activate
PPAR-α. As such, the lowering of triglycerides in vivo
by MBX-102 is not a PPAR-α mediated eﬀect, but is
rather mediated by an alternate mechanism which has
yet to be determined. Additional studies are required
to determine if MBX-102, like halofenate, is capable of
inhibiting liver triglyceride formation. More importantly,
studies designed to understand how such inhibition may
occur will be required. Among these, measurement of serum
and hepatic triglyceride formation and turnover will be
necessary.
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